title: Loss of muscle strength during sepsis is in part regulated by glucocorticoids and is associated with reduced muscle fiber stiffness.
abstract: Sepsis is associated with impaired muscle function but the role of glucocorticoids in sepsis-induced muscle weakness is not known. We tested the role of glucocorticoids in sepsis-induced muscle weakness by treating septic rats with the glucocorticoid receptor antagonist RU38486. In addition, normal rats were treated with dexamethasone to further examine the role of glucocorticoids in the regulation of muscle strength. Sepsis was induced in rats by cecal ligation and puncture, and muscle force generation (peak twitch and tetanic tension) was determined in lower extremity muscles. In other experiments, absolute and specific force as well as stiffness (reflecting the function of actomyosin cross bridges) were determined in isolated skinned muscle fibers from control and septic rats. Sepsis and treatment with dexamethasone resulted in reduced maximal twitch and tetanic force in intact isolated extensor digitorum longus muscles. The absolute and specific maximal force in isolated muscle fibers was reduced during sepsis together with decreased fiber stiffness. These effects of sepsis were blunted (but not abolished) by RU38486. The results suggest that muscle weakness during sepsis is at least in part regulated by glucocorticoids and reflects loss of contractility at the cellular (individual muscle fiber) level. In addition, the results suggest that reduced function of the cross bridges between actin and myosin (documented as reduced muscle fiber stiffness) may be involved in sepsis-induced muscle weakness. An increased understanding of mechanisms involved in loss of muscle strength will be important for the development of new treatment strategies in patients with this debilitating consequence of sepsis.
authors.affiliation: Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Nima
authors.initials: N
authors.lastname: Alamdari
authors.forename: Gianluca
authors.initials: G
authors.lastname: Toraldo
authors.forename: Zaira
authors.initials: Z
authors.lastname: Aversa
authors.forename: Ira
authors.initials: I
authors.lastname: Smith
authors.forename: Estibaliz
authors.initials: E
authors.lastname: Castillero
authors.forename: Guillaume
authors.initials: G
authors.lastname: Renaud
authors.forename: Rizwan
authors.initials: R
authors.lastname: Qaisar
authors.forename: Lars
authors.initials: L
authors.lastname: Larsson
authors.forename: Ravi
authors.initials: R
authors.lastname: Jasuja
authors.forename: Per-Olof
authors.initials: PO
authors.lastname: Hasselgren
mesh_terms: D000205:Actomyosin / Q000502:physiology; D000818:Animals; D001696:Biomechanical Phenomena; D005938:Glucocorticoids / Q000378:metabolism*; D008297:Male; D015735:Mifepristone / Q000494:pharmacology; D018485:Muscle Fibers, Skeletal / Q000502:physiology*; D053580:Muscle Strength / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors; D018805:Sepsis / Q000150:complications* / Q000473:pathology
chemical_list: D005938:Glucocorticoids; D011965:Receptors, Glucocorticoid; D015735:Mifepristone; D000205:Actomyosin